SCHEMBL1774641

SCHEMBL1774641

Cc1cccc(Cl)c1Sc1ccc2ccnc(N3CCN(C(=O)OC(C)(C)C)CC3)c2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 4/20 0.43
CNR1 P21554 1/20 0.43
CNR2 P34972 1/20 0.43
KIT P10721 2/20 0.42
ACHE P22303 2/20 0.42
GBA1 P04062 2/20 0.41
CCNK O75909 1/20 0.41
CCNA2 P20248 1/20 0.41
CDK2 P24941 1/20 0.41
CCND3 P30281 1/20 0.41
CDK9 P50750 1/20 0.41
CDK6 Q00534 1/20 0.41
TRPV1 Q8NER1 2/20 0.41
POLB P06746 1/20 0.40
PDE10A Q9Y233 1/20 0.39
HTR1A P08908 1/20 0.39
HTR1D P28221 1/20 0.39
HTR1B P28222 1/20 0.39
MAPK8 P45983 1/20 0.38
GRIA1 P42261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1773876 0.86 KIT (0.44) TRPA1CNR1CNR2KITACHE
SCHEMBL1775580 0.85 CNR1 (0.45) TRPA1CNR1CNR2KITACHE
SCHEMBL1775930 0.85 KIT (0.46) KITACHEGBA1PDE10AGRIA1
SCHEMBL1774920 0.84 HTR1A (0.40) TRPA1CNR2GBA1TRPV1HTR1A
SCHEMBL12601534 0.84 KIT (0.52) KITACHEGBA1POLBPDE10A
SCHEMBL1774286 0.84 KIT (0.45) KITACHEGBA1PDE10AGRIA1
SCHEMBL1775660 0.82 KIT (0.44) KITACHEGBA1PDE10AGRIA1
SCHEMBL12601538 0.81 PDE10A (0.51) KITACHEGBA1PDE10AGRIA1
SCHEMBL1775291 0.80 KIT (0.48) KITACHEGBA1TRPV1PDE10A
SCHEMBL17844999 0.80 KIT (0.49) TRPA1CNR1CNR2KITACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943639-B2 Such as 6-benzenesulfonyl-4-piperazin-1-yl-quinoline hydrochloride; for treatment of central nervous system and/or 5- HT6 receptor related disorders; for weight gain/loss PROXIMAGEN LIMITED (GB) 2011-05-17 US disclosed
EP-1897876-A2 Compounds useful for the treatment of obesity, type II diabetes and CNS disorders Biovitrum AB (publ) (SE) 2008-03-12 EP disclosed
EP-1513828-A1 NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS Biovitrum AB (SE) 2005-03-16 EP disclosed
US-20040024210-A1 New compounds PROXIMAGEN NEUROSCIENCE PLC (GB) 2004-02-05 US disclosed
WO-2004000828-A1 NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS BIOVITRUM AB (SE) 2003-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024210-A1 New compounds SULT1E1, SULT2A1, SULT1A1 TRPA1 1510/4885CNR1 69/4885CNR2 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.